CAR-T细胞疗法的差异性，而非多样性

1.Introduction a.Minutes and Overview Plan from February 2021 meeting (Attachment 1)b.Introduction of new upcoming Chair Sairah Ahmed, MD (MD Anderson Cancer) and assistantScientific Director Amy Moskop, MD, MSc.Instructions for sign-in and voting 2.Accrual summary(Attachment 2) 3.Presentations, published or submitted papers a.CT19-01Shadman M, Pasquini MC, Ahn KW, Chen Y, Turtle CJ, Hematti P, Cohen JB, Khimani F,Ganguly S, Merryman RW, Yared JA, Locke FL, Ahmed N, Munshi P, Beitinjaneh A, Reagan P,Herrera AF, Sauter CS, Kharfan-Dabaja MA, Hamadani M. Autologous transplant versus chimericantigen receptor T-cell therapy for relapsed DLBCL in partial remission. Blood.doi:10.1182/blood.2021013289. Epub 2021 Sep 27.b.AC17-01Park J, Nikiforow S, Kim S,Hu ZH, Moskop , Ahmed S, Abid MB, Badar T, Bredeson C,Brown V, Cairo MS, DíazM, Dholaria B, Ganguly S, Grover NS, Hanna R, Hematti P, Kohorst MA,Lazarus HM,Lekakis L, Locke FL, Murthy HS, Mussetti A, Pulsipher MA, Qayed M, Reshef R, RizzieriDA, Salas MQ, Savani BB, Sharma A, Schultz KR, Thakar M, Turtle C, Yared JA, Wagner JL, Qiu X,Pasquini MC, Perales MA. Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment ofRelapsed Acute Lymphoblastic Leukemia (ALL).Poster presentation, ASH 2021. c.SC17-08Samuel John, Michael A. Pulsipher, Amy Moskop, Zhen-Huan Hu,Christine L. Phillips, ErinMarie Hall, Steven P. Margossian, Sarah Nikiforow, Paul L. Martin, Benjamin Oshrine, Amy K.Keating, Rayne H. Rouce, Ranjan Tiwari, Santiago Redondo,Jennifer Willert,Abhijit Agarwal,Marcelo C Pasquini, and Stephan A. Grupp.Real-World Outcomes for Pediatric and Young AdultPatients with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL) Treated withTisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research(CIBMTR) Registry.Oral presentation,ASH 2021.d.SC17-08DanielJLandsburg, Matthew J. Frigault, Zhen-Huan Hu, Samantha Jaglowski, Frederick L.Locke, Christine Ho, Miguel-Angel Perales, Caron Jacobson, Brian T. Hill, Stephen Ronan Foley,Peter A.Riedell, Ranjan Tiwari, Aisha Masood,Stephen Lim, Marta Majdan,Marcelo C Pasquini,andCameron J. Turtle.Real-World Efficacy and Safety Outcomes for Patients with Relapsed orRefractory (R/R) Aggressive B-Cell Non-Hodgkin’s Lymphoma (aBNHL) Treated withCommercialTisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research(CIBMTR) Registry.Oral presentation,ASH 2021.e.SC17-07FrederickL.Locke,Caron Jacobson, Long Ma, Hua Dong, Zhen-Huan Hu, Tanya Siddiqi,Sairah Ahmed, Armin Ghobadi, David B. Miklos, Yi Lin, Miguel-Angel Perales, Matthew A. Lunning,Megan M. Herr, Brian T. Hill, Siddhartha Ganguly, Abu-Sayeef Mirza, Sarah Nikiforow, HairongXu,and Marcelo C Pasquini.Real-World Outcomes of Axicabtagene Ciloleucel (Axi-cel) for theTreatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ Dysfunction.Oralpresentation,ASH 2021.f.SC17-07Caron A. Jacobson, Frederick L. Locke, Zhen-Huan Hu, Tanya Siddiqi, Sairah Ahmed, ArminGhobadi, David B. Miklos, Yi Lin, Miguel-Angel Perales, Matthew A. Lunning, Megan Herr, Brian T.Hill, Siddhartha Ganguly, Hua Dong, Sarah Nikiforow, Jing Xie, HairongXu, Michele Hooper, JunKawashima, Marcelo C. Pasquini.Real-world evidence of axicabtagene ciloleucel (Axi-cel) for thetreatment of large B-cell lymphoma (LBCL) in the United States (US).Poster presentation,ASCO2021. 4.Studies in progress(Attachment 3) a.AC16-01Pattern of use and outcomes with donor lymphocyte infusion after HLA-haploidenticalallogeneic hematopoietic stem cell transplantManuscript prepb.AC17-01CAR-T with or without subsequent HCT for ALLManuscript prep/ Accepted ASH Abstractc.AC18-01Effect of stem cell boost and donor lymphocyte infusion on the incidence of GVHDProtocol Developmentd.CT19-02Prolonged cytopenia following CAR-T for DLBCLManuscript Prepe.CT20-01Comparison of commercial CAR T cells for DLBCLAnalysisf.CT20-02Health Resource utilization in CAR T cellsData file prepg.CT20-03Determinants of outcomes after CAR T cells for LymphomaAnalysish.CT20-04Determinants of outcomes after CAR T cells for ALLProtocol Developmenti.CT21-01Outcomes of elderly patients receiving CAR-T for DLBCLProtocol Development 5.Future/proposed studies a.PROP 2110-246Myelodysplastic Syndrome / Acute Myelogenous Leukemia after AutologousChimeric Antigen Receptor T-cell Immunotherapy for Non-Hodgkin Lymphoma (Dean)(Attachment4)b.PROP 2110-271Utilization Pattern of Subsequent Non-allogeneic Hematopoietic CellTransplantation Interventions after Chimeric Antigen Receptor T-cell therapy for B-cell AcuteLymphoblastic Leukemia: CIBMTR analysis (Murthy)and PROP 2110-292Outcomes of Second orSubsequent CAR-T infusion after relapse from prior CAR-T cell therapy (Mirza, Gowda)and PROP2110-68Safety and Efficacy of CD19 CAR T Cell Reinfusion in Pediatric Patients with B LineageAcuteLymphobla